Amgen Inc (LTS:0R0T)
$ 269.5 0 (0%) Market Cap: 174.85 Bil Enterprise Value: 226.24 Bil PE Ratio: 41.65 PB Ratio: 23.23 GF Score: 91/100

Amgen Inc Investor Call from AHA 2022 Transcript

Nov 07, 2022 / 11:00PM GMT
Release Date Price: $274.4 (+3.33%)
Operator

My name is [Jay Son], and I will be your conference facilitator today for Amgen's Analyst and Investor Conference Call at the 2022 American Heart Association Meeting. (Operator Instructions) I would now like to introduce David Reese, Executive Vice President of Research and Development. Mr. Reese, you may now begin.

David M. Reese
Amgen Inc. - EVP of Research & Development

Thanks, [Jay Son], and good afternoon and good evening, everyone. Thanks for joining us today for an update on our general medicine portfolio, selected molecules in development. We have a lot of material to cover today, some interesting new data, and so we'll move right into the program.

On the next slide, you can see our standard safe harbor statement. And on the following slide, you see the agenda for today's call. I'll provide a very brief introduction with some context setting. And then, Professor Marc Sabatine, who's a Professor of Medicine at Harvard Medical School, Chair in Cardiovascular Medicine at the Brigham and Women's Hospital and the Chair of the TIMI Study Group,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot